Johnson & Johnson: completes sale of diabetes control unit

(CercleFinance.com) - Johnson & Johnson has completed the divestiture of its blood glucose monitoring unit LifeScan to Platinum Equity for approximately 2.
1 billion dollars, the US healthcare giant said on Monday.

LifeScan - which is the maker of the OneTouch brand of products - generated net revenues of approximately 1.5 billion dollars in 2017.

J&J said it will continue to focus on diabetes patients through products, services and solutions such as weight-loss surgery and through medicines, such as Invokana.

Copyright (c) 2018 CercleFinance.com. All rights reserved.